Browse > Article
http://dx.doi.org/10.12925/jkocs.2009.26.2.8

Synthesis and Melanoma Inhibitory Activity of New Aminoisoquinolinylamide Derivatives  

Yoo, Kyung-Ho (Biomaterials Research Center, Korea Institute of Science and Technology)
Cho, Hye-Jung (Biomaterials Research Center, Korea Institute of Science and Technology)
Publication Information
Journal of the Korean Applied Science and Technology / v.26, no.2, 2009 , pp. 161-170 More about this Journal
Abstract
In this work, a novel series of aminoisoquinolinylamide derivatives 1a-c and 2a-f were synthesized via several reaction steps, starting from 2-methyl-4-nitrobenzonitrile (3) and 1-chloro-5-nitroquinoline (8). And their antiproliferative activities were screened against A375 human melanoma cell line compared to Sorafenib as a reference compound. Among them, compound 1b and 1c exhibited meaningful inhibitory activities. These results demonstrated that aminoisoquinolinylamide scaffold possesses the possibility as the treatment for melanoma.
Keywords
aminoisoquinolinylamides; synthesis; antiproliferative activity; melanoma cell line;
Citations & Related Records
연도 인용수 순위
  • Reference
1 F. R. Gruijl, UV Carcinogenesis and Melanocytes, Pigment Cell Res., 16, 591 (2003)
2 A. C. Buzaid and C. M. Anderson, The Changing Prognosis of Melanoma, Curro Oneol. Rep., 2, 322 (2000)   DOI   ScienceOn
3 S. A. Rosenburg, M. T. Lotze, J. C. Yang, P. M. Aebersold, W. M. Linehan, C. A. Seipp, and D. E. White, Experience with the Use of High Dose Interleukin-2 in the Treatment of 652 Cancer Patients, Ann. Surg., 210, 474 (1989)   DOI   ScienceOn
4 C. M. Anderson, A. C. Buzaid, and S. S. Legha, Systemic Treatments for Advanced Cutaneous Melanoma, Oncology, 9, 1149 (1995)
5 L. Serrone, M. Zeuli, F. M. Sega, and F. Cognetti, therapy Dacarbazine-based Chemofor Metastatic Melanoma: Thirty-year Experience Overview, J. Exp. Clin. Cancer Res., 19, 21 (2000)
6 W. S. Fletcher, D. S. Daniels, V. K. Sondak, B. Dana, R. Townsend, H. E. Hynes, L. F. Hutchins, and J. R. Pancoast. Evaluation of Cisplatin and DTIC in Inoperable Stage III and IV Melanoma, Am J. Clin. Oneol., 16, 359 (1993)   DOI   ScienceOn
7 S. A. Gamage, J. A. Spicer, G. W. Rewcastle, J. Milton, S. Sohal, W. Dangerfield, P. Mistry, N. Vicker, P. A. Charlton, and W. A. Denny, Structure-activity Relationships for Pyrido-, Imidazo-, Pyrazolo-, Pyrazino-, and Pyrrolophenazinecarboxamides as Topoisomerase-targeted Anticancer Agents, J. Med. Chern., 45, 740 (2002)   DOI   ScienceOn
8 D. H. Lawson, Choices in Adkuvant Trerapy of Melanoma, Cancer Control, 12, 236 (2005)   DOI   PUBMED
9 A. Y. Bedikian, M. Mill ward, H. Pehamberger, R. Conry, M. Gore, U. Trefzer, A. C. Pavlick, R. DeConti, E. M. Hersh, P. Hersey, J. M. Kirkwood, and F. G. Haluska, Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group, J. Clin. Oneol., 24, 4738 (2006)   DOI   ScienceOn
10 L. V. Dubey, and I. V. Dubey, Side Reactions of Onium Coupling Reagents BOP and HBTV in the Synthesis of Silica Polymer Supports, Ukr. Bioorg. Acta, 1, 13 (2005)
11 B. J. Druker and N. B. Lydon, Lessons Learned from the Development of an Abl Tyrosine Kinase Inhibitor for Chronic Myelogenous Leukemia, J. Clin. Invest., 105, 3 (2000)   DOI   ScienceOn
12 M. R. Middleton, J. J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates, B. Dreno, M. Henz, D. Schadendorf, A. Kapp, J. Weiss, U. Fraass, P. Statkevich, M. Muller, and N. Thatcher, Randomized Phase III Study of Temozolomide versus Dacarbazine in the Treatment of Patients with Advanced Metastatic Malignant Melanoma, J. Clin. Oneal., 18, 158 (2008)
13 X. Zhang, A. Nirschl, Y. Zou, and E. S. Priestley, Phenylglycinarnide and Pyridylglycinamide Derivatives Useful as Anticoagulants, WO 07/002313
14 J. A. Carlson, J. S. Ross, A. Slominski, G. Linette, J. Mysliborski, J. Hill, and M. Mihm, Jr., Molecular Diagnostics in Melanoma, J. Am Acad. Dermntol., 52, 743 (2005)   DOI   ScienceOn
15 M. B. Atkins, M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, and S. A. Rosenberg, High-dose Recombinant Interleukin 2 Therapy for Patients with Metastatic Melanoma: Analysis of 270 Patients Treated between 1985 and 1993, J. Clin. Oneol., 17, 2105 (1999)   DOI
16 S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch, Preclinical Overview of Sorafenib, a Multikinase Inhibitor that Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling, Mol. Cancer Ther., 7, 3129 (2008)   DOI   ScienceOn
17 D. Raben, B. A. Helfrich, D. Chan, G. Johnson, and P. A. Bunn, Jr., ZD1839, A Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Alone and in Combination with Radiation and Chemotherapy as a New Therapeutic Strategy in Non-small Cell Lung Cancer, Semin. Oneol., 29 (Supplement 4), 37 (2002)
18 C. Garbe, A. Hauschild, M. V olkenandt, D. Schadendorf, W. Stolz, u. Reinhold, R. D. Kortmann, C. Kettelhack, B. Frerich, U. Keilholz, R. Dummer, G. Sebastian, W. Tilgen, G. Schuler, A. Mackensen, and R. Kaufmann, Evidence and Interdisciplinary Consense-based German Guidelines: Diagnosis and Surveillance of Melanoma, Melanoma Res., 17, 393 (2007)   DOI   ScienceOn
19 R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. M. Clark, P. Santabarbara, and P. Bonomi, Determinants of Tumor Response and Survival with Erlotinib in Patients with Non - Small-Cell Lung Cancer, J. Clin. Oneol., 22, 3238 (2004)   DOI   ScienceOn